Subtitle: Master dedifferentiated liposarcoma vs pleomorphic liposarcoma pathology. Review morphology, pleomorphic lipoblasts, MDM2 FISH, IHC, virtual slides and 10 interactive MCQs.

Author: PathologyMCQ Editorial Board

Category: Soft Tissue Pathology / WHO Bone and Soft Tissue Tumours

Last Updated: October 2026

Read Time: 12 minutes

This is a medical, educational, exam-oriented pathology review focused on diagnosis and histopathology.

At-a-Glance Diagnostic Summary

• Difficulty Level: Advanced / Board Review (Pathology Residents & Fellows)
• Defining Molecular Distinction: Dedifferentiated Liposarcoma (DDLPS) harbors 12q13-15 amplification (MDM2, CDK4, CPM); Pleomorphic Liposarcoma (PLPS) exhibits a chaotic karyotype with frequent TP53 and RB1 mutations and lacks MDM2 amplification.
• Key Microscopic Hallmark: DDLPS displays a transition from well-differentiated lipogenic tumor to non-lipogenic sarcoma; PLPS requires the identification of genuine pleomorphic lipoblasts in a high-grade pleomorphic background.
• Predominant Anatomical Sites: DDLPS arises primarily in the retroperitoneum (>75%); PLPS develops predominantly in the deep soft tissues of the extremities (lower extremity > upper extremity).

What Are the Core Differences in Dedifferentiated Liposarcoma vs Pleomorphic Liposarcoma?

Dedifferentiated liposarcoma (DDLPS) and pleomorphic liposarcoma (PLPS) represent distinct biological and clinicopathologic entities within the World Health Organization (WHO) classification of soft tissue sarcomas. DDLPS is a high-grade malignancy defined by the progression of well-differentiated liposarcoma (WDLPS) / atypical lipomatous tumor (ALT) into a non-lipogenic sarcomatous component, characterized genetically by 12q13-15 gene amplification. In contrast, PLPS is an aggressive, non-amplified lipogenic malignancy arising de novo that features high-grade pleomorphic tumor cells intermixed with diagnostic multi-vacuolated pleomorphic lipoblasts.

Microscopically, DDLPS exhibits dual architecture where mature adipose or low-grade sclerosing liposarcomatous areas sit in direct juxtaposition to high-grade spindle cell or pleomorphic sheets that have lost all adipocytic differentiation. In contrast, PLPS does not produce a low-grade precursor component; its defining hallmark is the presence of multi-vacuolated pleomorphic lipoblasts featuring hyperchromatic, scalloped nuclei driven by intracytoplasmic lipid droplets. Recognizing this architectural difference is critical on diagnostic biopsy specimens.

What Are the Distinct Pathogenetic Pathways of DDLPS and PLPS?

The pathogenetic difference between DDLPS and PLPS lies in whether tumor evolution occurs as a secondary dedifferentiation event or as a primary, de novo oncogenic transformation. DDLPS arises through clonal evolution and secondary genomic hits within a pre-existing well-differentiated liposarcoma/atypical lipomatous tumor, whereas PLPS arises spontaneously without a pre-existing low-grade adipocytic precursor.

The progression from WDLPS to DDLPS is driven by the baseline MDM2 amplification liposarcoma signature on supernumerary ring or giant marker chromosomes, supplemented by secondary alterations such as 1p32 (JUN) amplification, 6q23 amplification, or 9p21 (CDKN2A) deletions. Conversely, PLPS develops de novo without MDM2 amplification, relying on extensive chromosomal rearrangements, early functional inactivation of cell-cycle checkpoints (TP53 and RB1), and chromosomal instability.

• Diagnostic Pitfall: When a core needle biopsy samples only the high-grade non-lipogenic region of a retroperitoneal DDLPS, it can morphologically mimic undifferentiated pleomorphic sarcoma (UPS) or PLPS. Ancillary molecular testing for MDM2 amplification is mandatory in this setting.

How Do DDLPS and PLPS Differ on Histopathologic Examination?

Histopathologic evaluation requires identifying whether lipogenic differentiation is restricted to a low-grade precursor zone or integrated throughout the high-grade pleomorphic tumor as diagnostic lipoblasts. DDLPS is defined by an abrupt or transitional boundary between low-grade lipomatous components and high-grade non-lipogenic sarcoma, whereas PLPS displays high-grade pleomorphic morphology containing bona fide pleomorphic lipoblasts histology.

Microscopic Architecture of DDLPS

• Well-Differentiated Component: Atypical mature adipocytes showing variation in cell size, focal hyperchromatic stromal spindle cells in fibrous septa, and variable univacuolar lipoblasts.
• Dedifferentiated Component: Cellular sheets of non-lipogenic spindle cells or pleomorphic cells, frequently mimicking undifferentiated pleomorphic sarcoma, myxofibrosarcoma, or high-grade fibrosarcoma.
• Heterologous Elements: Observed in approximately 5–15% of DDLPS cases, including rhabdomyoblastic, osteosarcomatous, chondrosarcomatous, or leiomyosarcomatous differentiation.
• Lipogenic Status: The dedifferentiated component is entirely non-lipogenic; true pleomorphic lipoblasts are absent in this zone.

Microscopic Architecture of PLPS

• Tumor Composition: Highly cellular, sheet-like architecture composed of bizarre multi-nucleated giant cells, spindle cells, and high mitotic activity with atypical figures.
• Pleomorphic Lipoblasts: Hallmark diagnostic cells containing multiple, sharply demarcated, lipid-rich intracytoplasmic vacuoles that scallop, indent, and deform hyperchromatic, pleomorphic nuclei.
• Absence of Low-Grade Areas: Entirely devoid of well-differentiated liposarcoma / atypical lipomatous components.
• Diagnostic Pitfall: Multivacuolated histiocytes (xanthoma cells), degenerative pseudolipoblasts, and signet-ring adenocarcinoma cells can mimic lipoblasts. True pleomorphic lipoblasts must have hyperchromatic, atypical, scalloped nuclei.

What Are the Defining Molecular and Cytogenetic Alterations?

The definitive diagnostic separation of DDLPS from PLPS rests on targeted cytogenetic and molecular analyses. DDLPS is defined by high-grade liposarcoma molecular genetics characterized by 12q13-15 amplifications, while PLPS shows a chaotic karyotype lacking 12q amplification.

Molecular Genetics of DDLPS

• Primary Alteration: Amplification of the 12q13-15 region, containing key oncogenes:
  • MDM2 (12q15): Overexpression inhibits p53-mediated tumor suppression.
  • CDK4 (12q14.1): Drives cell-cycle progression past the G1/S checkpoint via RB phosphorylation.
  • CPM, HMGA2, TSPAN31, FRS2: Co-amplified oncogenes within the 12q amplicon.
• Cytogenetic Structures: Present as supernumerary ring chromosomes and giant marker chromosomes.
• Diagnostic Gold Standard: Dual-color fluorescence in situ hybridization (FISH) demonstrating MDM2 amplification (MDM2/CEP12 ratio ≥ 2.0 or >6 MDM2 signals per nucleus).
• Immunohistochemistry: Diffuse, strong nuclear positivity for MDM2 and CDK4.

Molecular Genetics of PLPS

• Karyotype: Complex, aneuploid, and highly rearranged karyotype without recurrent driver amplifications.
• Key Inactivations: High frequency of bi-allelic loss or mutations in TP53 (up to 60%) and RB1.
• Amplification Status: Negative for MDM2 and CDK4 amplification by FISH.
• Immunohistochemistry: Negative for nuclear MDM2/CDK4; aberrantly strong diffuse positive or completely null p53 staining pattern; loss of Rb expression.

How Does Anatomical Distribution Impact Clinical Presentation and Staging?

Anatomical localization differs significantly between these two malignancies, directly affecting surgical resectability, recurrence patterns, and distant metastatic risk. DDLPS shows a heavy predilection for the retroperitoneum and deep trunk, whereas PLPS arises overwhelmingly in the deep muscular compartments of the extremities.

DDLPS vs PLPSWhere they arise

DDLPSPLPS

DDLPS

• Retroperitoneum: over 75%
• Also spermatic cord and mediastinum
• Extremities: uncommon

PLPS

• Deep soft tissue of the extremities, especially the thigh
• Then upper limb and trunk
• Retroperitoneum: rare

Clinical behaviour

• DDLPS: local recurrence is the main problem
• PLPS: higher risk of haematogenous spread, mainly to the lungs

Exam pearl: a retroperitoneal pleomorphic sarcoma is DDLPS until MDM2 testing proves otherwise.

Clinical Profiles and Topography

• Dedifferentiated Liposarcoma (DDLPS):
  • Topography: Retroperitoneum (>75%), deep pelvic/abdominal cavity, and spermatic cord / paratesticular soft tissue. Extremity occurrence is rare.
  • Clinical Presentation: Often asymptomatic until reaching massive proportions, presenting with abdominal fullness, early satiety, or palpable abdominal masses.
  • Behavior: High local recurrence rate due to anatomical constraints in achieving negative surgical margins; distant metastatic rate is approximately 15–30%.
• Pleomorphic Liposarcoma (PLPS):
  • Topography: Deep soft tissues of the extremities, particularly the thigh, lower leg, and upper limb. Retroperitoneal involvement is exceptionally rare.
  • Clinical Presentation: Rapidly growing, deep-seated, painful or painless soft-tissue mass.
  • Behavior: Highly aggressive with early hematogenous dissemination; distant metastatic rate reaches 30–50% (primarily to the lungs), with an overall 5-year survival rate of approximately 55–65%.

Comparative Summary Table: DDLPS vs. PLPS

Feature	Dedifferentiated Liposarcoma (DDLPS)	Pleomorphic Liposarcoma (PLPS)
Pathogenesis	Progression / dedifferentiation from pre-existing WDLPS/ALT	De novo development without low-grade precursor
Primary Anatomical Sites	Retroperitoneum (>75%), spermatic cord, mediastinum	Deep soft tissue of extremities (thigh, upper limb)
Key Histopathology	Biphasic: low-grade lipomatous transition to non-lipogenic sarcoma	High-grade pleomorphic sarcoma with pleomorphic lipoblasts
Lipoblast Characteristics	Absent in dedifferentiated areas; univacuolar in WDLPS zone	Prominent, atypical, multi-vacuolated with scalloped nuclei
Heterologous Differentiation	Present in 5–15% (rhabdo-, osteo-, chondro-, leiomyosarcomatous)	Rare
Cytogenetics	Supernumerary rings / giant markers; 12q13-15 amplification	Complex, chaotic karyotype with aneuploidy; no 12q amplification
Key Driver Genes	MDM2, CDK4, HMGA2, CPM, FRS2	TP53, RB1 (inactivation/loss)
IHC Profile	Nuclear MDM2 (+), CDK4 (+), p16 (+)	MDM2 (-), CDK4 (-), aberrant/null p53, loss of Rb
FISH Diagnostic Standard	MDM2 gene amplification (MDM2/CEP12 ≥ 2.0)	Negative for MDM2 amplification
Metastatic Rate	15–30% (predominantly local recurrences drive mortality)	30–50% (rapid pulmonary hematogenous dissemination)

WHO 6th Edition: What Changed for DDLPS and PLPS?

High-Yield Board Examination MCQs

Exam Pearls & Key Takeaways

• Exam Pearl: Any retroperitoneal “undifferentiated pleomorphic sarcoma” is considered dedifferentiated liposarcoma until proven otherwise by MDM2 FISH.
• Key Takeaway: DDLPS develops secondary to 12q13-15 (MDM2/CDK4) amplification from WDLPS and lacks lipoblasts in its high-grade zones, whereas PLPS arises de novo in the extremities as an MDM2-negative pleomorphic sarcoma containing diagnostic pleomorphic lipoblasts.

Video lesson

Lipoma vs well-differentiated liposarcoma (ALT), explained

Every DDLPS starts as WDLPS/ALT. Learn to separate it from lipoma first: atypical stromal cells, thick fibrous septa and MDM2 amplification.

Recommended course

Approach-Based Histopathology & Cytology

• Low-power approaches to soft tissue tumours and every other system
• Slide videos that walk you from pattern to diagnosis
• Built by practising pathologists for sign-out and exams

Explore the Approach course →